AZN.UK

11,120

-2.78%↓

GSK

1,423.5

-4.37%↓

HLN.UK

386.9

-2.03%↓

INDV

730.5

-0.61%↓

AZN.UK

11,120

-2.78%↓

GSK

1,423.5

-4.37%↓

HLN.UK

386.9

-2.03%↓

INDV

730.5

-0.61%↓

AZN.UK

11,120

-2.78%↓

GSK

1,423.5

-4.37%↓

HLN.UK

386.9

-2.03%↓

INDV

730.5

-0.61%↓

AZN.UK

11,120

-2.78%↓

GSK

1,423.5

-4.37%↓

HLN.UK

386.9

-2.03%↓

INDV

730.5

-0.61%↓

AZN.UK

11,120

-2.78%↓

GSK

1,423.5

-4.37%↓

HLN.UK

386.9

-2.03%↓

INDV

730.5

-0.61%↓

Search

Hikma Pharmaceuticals PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

1,917 -2.29

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1896

Max

1971

Pagrindiniai rodikliai

By Trading Economics

Pajamos

226M

Pardavimai

1.6B

P/E

Sektoriaus vid.

29.53

63.778

Pelnas, tenkantis vienai akcijai

1.27

Dividendų pajamingumas

3.11

Pelno marža

14.404

Darbuotojai

9,500

EBITDA

499M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+24.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.11%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-717M

4.4B

Ankstesnė atidarymo kaina

1919.29

Ankstesnė uždarymo kaina

1917

Naujienos nuotaikos

By Acuity

22%

78%

50 / 386 reitingas Healthcare

Hikma Pharmaceuticals PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 23:46; UTC

Rinkos pokalbiai

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-04-01 23:43; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025-04-01 23:11; UTC

Svarbiausios naujienos

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025-04-01 23:02; UTC

Rinkos pokalbiai

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 22:26; UTC

Rinkos pokalbiai

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:32; UTC

Svarbiausios naujienos

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025-04-01 21:06; UTC

Rinkos pokalbiai

Mexican Remittances See Slow Start to the Year -- Market Talk

2025-04-01 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-04-01 20:47; UTC

Svarbiausios naujienos

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025-04-01 20:47; UTC

Svarbiausios naujienos

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025-04-01 20:20; UTC

Svarbiausios naujienos

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025-04-01 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Fibrebond >ETN

2025-04-01 20:11; UTC

Rinkos pokalbiai

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025-04-01 20:00; UTC

Svarbiausios naujienos

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025-04-01 19:46; UTC

Svarbiausios naujienos

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025-04-01 19:43; UTC

Rinkos pokalbiai

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025-04-01 19:17; UTC

Svarbiausios naujienos

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025-04-01 19:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025-04-01 19:03; UTC

Rinkos pokalbiai

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025-04-01 19:00; UTC

Rinkos pokalbiai

Gold Slips Ahead of Tariff Day -- Market Talk

2025-04-01 18:54; UTC

Rinkos pokalbiai

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hikma Pharmaceuticals PLC Prognozė

Kainos tikslas

By TipRanks

24.59% į viršų

12 mėnesių prognozė

Vidutinis 2,427 GBX  24.59%

Aukščiausias 2,650 GBX

Žemiausias 2,000 GBX

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hikma Pharmaceuticals PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

4

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

50 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.